KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Buildings (2009 - 2022)

Amgen's quarterly Buildings came in at $4.2 billion in Q4 2022, up 4.29% year-on-year from $4.0 billion in Q4 2021, and up 4.29% quarter-over-quarter from $4.0 billion in Q4 2021.

Amgen has reported Buildings for 14 years, with the latest figure at $4.2 billion in Q4 2022.

  • For the quarter ending Q4 2022, Buildings rose 4.29% year-over-year to $4.2 billion; the trailing twelve-month figure through Dec 2022 stood at $4.2 billion (up 4.29% YoY), and the FY2022 full-year result was $4.2 billion, up 4.29% from the prior year.
  • Buildings for Q4 2022 stood at $4.2 billion, up from $4.0 billion in the prior quarter.
  • The five-year high for Buildings was $4.2 billion in Q4 2022, with the low at $3.6 billion in Q4 2018.
  • Average Buildings over 5 years is $3.9 billion, with a median of $3.9 billion recorded in 2020.
  • Year-over-year, Buildings increased 2.66% in 2020 and climbed 4.43% in 2021.
  • Tracing AMGN's Buildings over 5 years: stood at $3.6 billion in 2018, then grew by 3.9% to $3.8 billion in 2019, then increased by 2.66% to $3.9 billion in 2020, then grew by 4.43% to $4.0 billion in 2021, then increased by 4.29% to $4.2 billion in 2022.
  • The last three Buildings figures came in at $4.2 billion (Q4 2022), $4.0 billion (Q4 2021), and $3.9 billion (Q4 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 4.20 Bn
Dec 31, 2021 4.03 Bn
Dec 31, 2020 3.86 Bn
Dec 31, 2019 3.76 Bn
Dec 31, 2018 3.62 Bn
Dec 31, 2017 3.51 Bn
Dec 31, 2016 3.64 Bn
Dec 31, 2015 3.64 Bn
Dec 31, 2014 3.61 Bn
Dec 31, 2013 3.47 Bn
Dec 31, 2012 3.51 Bn
Dec 31, 2011 3.46 Bn
Dec 31, 2010 3.39 Bn
Dec 31, 2009 3.29 Bn